Conditions: Primary Myelofibrosis (PMF) Post Polycythaemia Myelofibrosis (PPV MF) Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Keywords: Ruxolitinib INC424 myelofibrosis PMF post polycythemia myelofibrosis PPV MF post-essential thrombocythemia myelofibrosis PET-MF Primary Myelofibrosis Polycythemia Thrombocythemia Essential Thrombocytosis myeloproliferative Disorders Bone Marrow Diseases Haematologic Diseases Blood Coagulation Disorders Blood Platelet Disorders Haemorrhagic Disorders
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 48
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate the efficacy of INC424 in patients with PMF, PPV MF, or PET-MF using a composite measure of either an objective endpoint (\> 50% reduction in splenomegaly using palpitation at 48 weeks) and/or a subjective endpoint (\>50% reduction in total symptom score at 48 weeks).

Detailed description:

Arms:
arm 1: Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.

Interventions: intervention 1: INC424
Intervention descriptions: intervention 1: Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.

Protocol document: